drugset / Trial / NCT04674345
Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allo-HSCT Recipients With FLT3 Negative Acute Leukemia
Phase 2/3
Unknown
346 enrolled
Nanfang Hospital, Southern Medical University
First People's Hospital of Chenzhou · collabPeking University People's Hospital · collabSecond Affiliated Hospital, Sun Yat-Sen University · collabThe First Affiliated Hospital of Guangzhou Medical University · collabThe Seventh Affiliated Hospital of Sun Yat-sen University · collabThe Third Xiangya Hospital of Central South University · collabThird Affiliated Hospital, Sun Yat-Sen University · collabXiangya Hospital of Central South University · collabZhujiang Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of sorafenib maintenance after allo-HSCT in FLT3-negative acute leukemia patients.
Timeline
- Start
- 2020-12-15
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |